Given a passage classify if the passage has a definite objective/aim/goal or not. Output '1' if the passage has a defininte objective/aim/goal and output '0' if the passage does not have a definite objective/aim/goal.

[Q]: The apoptosis inhibitor-5 (API5), anti-apoptosis protein, is considered a key molecule in the tumor progression and malignant phenotype of tumor cells. Here, we investigated API5 expression in cervical cancer, its clinical significance, and its relationship with phosphorylated extracellular signal-regulated kinase 1 and 2 (pERK1/2) in development and progression of cervical cancer.', 'API5 effects on cell growth were assessed in cervical cancer cell lines. API5 and pERK1/2 immunohistochemical staining were performed on a cervical cancer tissue microarray consisting of 173 primary cervical cancers, 306 cervical intraepithelial neoplasias (CINs), and 429 matched normal tissues.', 'API5 overexpression promoted cell proliferation and colony formation in CaSki cells, whereas API5 knockdown inhibited the both properties in HeLa cells. Immunohistochemical staining showed that API5 expression increased during the normal to tumor transition of cervical carcinoma (P\u2009<\u20090.001), and this increased expression was significantly associated with tumor stage (P\u2009=\u20090.004), tumor grade (P\u2009<\u20090.001), and chemo-radiation response (P\u2009=\u20090.004). API5 expression levels were positively associated with pERK1/2 in cervical cancer (P\u2009<\u20090.001) and high grade CIN (P\u2009=\u20090.031). In multivariate analysis, API5+ (P\u2009=\u20090.039) and combined API5+/pERK1/2+ (P\u2009=\u20090.032) were independent prognostic factors for overall survival.
[A]: 0


[Q]: Little is known about endothelial function in adolescents with type 1 diabetes, and we evaluated endothelial dysfunction, using reactive hyperaemia peripheral arterial tonometry (RH-PAT).', 'This prospective, observational, 1-year study focused on 73 adolescents with type 1 diabetes, using multiple daily injections or continuous subcutaneous insulin infusion. The subjects were assessed using RH-PAT, body mass index, blood pressure, fasting lipid profile, glycated haemoglobin, insulin requirements and hours of physical exercise per week.', 'Endothelial dysfunction was observed in 56 patients (76.7%), with lower mean RH-PAT scores (1.26\xa0±\xa00.22 versus 2.24\xa0±\xa00.48, p\xa0<\xa00.0001) and higher glycated haemoglobin values at baseline (8.27\xa0±\xa01.24% versus 7.37\xa0±\xa00.54%, p\xa0=\xa00.006) and as a mean of the whole period since diagnosis (8.25\xa0±\xa01.22% versus 7.72\xa0±\xa00.82%, p\xa0=\xa00.034). A higher percentage of patients with endothelial dysfunction showed abnormal cardiac autonomic tests (p\xa0=\xa00.02) and were more sedentary, exercising <4 hours a week, than patients with normal endothelial function. After follow-up in 64/73 patients, we observed endothelial dysfunction in 81.8% of patients, despite a modest improvement in glycated haemoglobin.
[A]: 1


[Q]: Altered nitric oxide (NO) signaling has been associated with the pathophysiology of Bipolar Disorder (BD), directly affecting neurotransmitter release and synaptic plasticity cascades. Lithium has shown to regulate NO levels in preclinical models. However, no study has addressed peripheral NO levels in unmedicated BD. Also, lithium's effects on NO levels have not been studied in humans.", 'Plasma NO was evaluated in subjects with BD I and II during a depressive episode (n\xa0=\xa026). Subjects had a score of ≥18 in the 21-item Hamilton Depression Rating Scale and were followed-up during a 6-week trial with lithium. Plasma NO levels were also compared to matched healthy controls (n\xa0=\xa028). NO was determined by chemiluminescence method.', 'Lithium treatment significantly increased plasma NO levels after 6 weeks of treatment in comparison to baseline levels in bipolar depression (p\xa0=\xa00.016). Baseline NO levels during depressive episodes showed no difference when matching up to healthy controls (p\xa0=\xa00.66).
[A]:
0